Novo Nordisk A/S $NVO Stock Position Reduced by SG Americas Securities LLC

SG Americas Securities LLC decreased its position in Novo Nordisk A/S (NYSE:NVO) by 81.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 472,124 shares of the company’s stock after selling 2,063,222 shares during the quarter. SG Americas Securities LLC’s holdings in Novo Nordisk A/S were worth $17,351,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in NVO. Godfrey Financial Associates Inc. acquired a new position in Novo Nordisk A/S in the fourth quarter worth $25,000. WealthCollab LLC increased its stake in Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after purchasing an additional 260 shares during the last quarter. American National Bank & Trust acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter worth $28,000. Maseco LLP acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter worth $29,000. Finally, Jackson Grant Investment Advisers Inc. bought a new position in shares of Novo Nordisk A/S in the 4th quarter worth about $29,000. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Up 0.3%

Novo Nordisk A/S stock opened at $47.55 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $71.79. The company has a 50-day simple moving average of $43.65 and a 200-day simple moving average of $45.81. The firm has a market capitalization of $212.32 billion, a P/E ratio of 11.16, a P/E/G ratio of 4.24 and a beta of 0.78.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. The firm had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. As a group, equities analysts expect that Novo Nordisk A/S will post 3.45 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $41.00 price target (down from $63.00) on shares of Novo Nordisk A/S in a report on Monday, March 2nd. Weiss Ratings cut shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, April 22nd. Nordea Equity Research upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Friday, June 19th. Sanford C. Bernstein initiated coverage on Novo Nordisk A/S in a report on Wednesday, March 18th. They set an “outperform” rating and a $175.00 target price for the company. Finally, Wall Street Zen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Five research analysts have rated the stock with a Buy rating, seventeen have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.